Literature Collection
12K+
References
11K+
Articles
1600+
Grey Literature
4800+
Opioids & SU
The Literature Collection contains over 11,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More
Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).
This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
Objective: Depression is the most common psychiatric comorbidity among people with opioid use disorders (OUDs). However, whether and how comorbid depression is associated with the outcomes of opioid agonist therapy (OAT) remains poorly understood. The objective of this review was to identify and describe the association between depression and main outcomes (opioid use and treatment retention) of methadone and buprenorphine treatment among people with OUDs. Methods: A literature review was conducted by searching five electronic databases (MEDLINE, PubMed, Embase, Evidence-Based Medicine Reviews [EBMR], and Cumulative Index of Nursing and Allied Health Literature [CINAHL] Complete) from January 1970 to April 2019. Two independent reviewers screened titles and abstracts of the identified records by using pre-established eligibility criteria. Next, full texts were reviewed and studies that met inclusion criteria were selected. Finally, a descriptive synthesis of extracted data was performed. Results: In total, 12,296 records were identified and 18 studies that met inclusion criteria were retained. Of these, six studies reported reduced opioid use and seven reported increased opioid use during methadone or buprenorphine treatment. In addition, three studies reported an increased retention rate and four documented a decreased retention rate during methadone or buprenorphine treatment. The remaining studies did not find any significant association between depression and opioid use or treatment retention. Overall, the evidence did not demonstrate a consistent association between depression and outcomes of methadone or buprenorphine treatment. Conclusions: Although the inconsistent nature of the current evidence prohibited us from drawing definitive conclusions, we posit that the presence of depression among OUDs patients may not always predict negative outcomes related to retention and drug use during the course of OAT. Particularly, the hypothesis that adequate treatment of depression can improve treatment retention is promising and is in line with the call for increased efforts to provide integrated care for comorbid mental health disorders and addiction. Future studies with rigorous methodology are essential to better characterize the complex interplay between depression, OAT, and OUDs.
PURPOSE: Adolescent depression screening in primary care is recommended yet little is known about its implementation and outcomes. We assessed rates of screening, "positive" screening and later diagnosis of depression. METHODS: This retrospective cohort study included 751,876 adolescents aged 11-17.99 years from 1/1/2017-12/31/2021 at a large integrated healthcare system in Southern California with comprehensive electronic medical records (EMR). Screening for depression was implemented at primary care using the abbreviated Patient Health Questionnaire (PHQ). All data were extracted from EMR. Rates of depression screening completion, screening "positive", and subsequent diagnosis of depression were reported overall; by age, gender, race/ethnicity, and estimated household income with Poisson regression comparing rates across subgroups. RESULTS: Among the adolescents, 613,662 (81.6 %) had primary care visits, of these, 403,890 (65.8 %) completed at least one screening during the study period. Although statistically significant, screening rates were generally comparable across age, gender, household income and race/ethnicity. A total of 9.7 % adolescents screened "positive", with some differences within subgroups. Among adolescents with "positive" screening, 30.2 % were diagnosed with depression within two years after the first "positive" screening, with some differences within subgroups. Adolescents self-identified as other gender had substantially higher rate of "positive" screening and diagnosis rate; however, the data was based on a sample size less than 50. CONCLUSION: Depression screening can be administered at primary care for adolescents starting as early as age 11 years old. Screening with PHQ at primary care as part of standard preventive care can effectively identify adolescents at risk for depression.
Pagination
Page 164 Use the links to move to the next, previous, first, or last page.
